VASOPRESSOR-RESISTANT HYPOTENSION, COMBINATION VASOPRESSOR THERAPY, AND SHOCK PHENOTYPES IN CRITICALLY ILL ADULTS WITH VASODILATORY SHOCK.

"R.M. reported receiving grants from National Institute of Diabetes and Digestive and Kidney Diseases and consulting fees from Baxter Inc. unrelated to this study and received grant funding from La Jolla Inc. for the current work. J.A.K. has received grant support and/or consulting fees from Astute Medical/BioMerieux, outside the submitted work. G.C. has received funding from the National Institutes of Health unrelated to the submitted work. L.S.C. was previously the chief medical officer of La Jolla Pharmaceuticals Inc. C.-C.H.C. has received grants from National Institutes of Health unrelated to this study. P.P. reports no conflicts of interest."

"R.M. reported receiving grants from National Institute of Diabetes and Digestive and Kidney Diseases and consulting fees from Baxter Inc. unrelated to this study and received grant funding from La Jolla Inc. for the current work. J.A.K. has received grant support and/or consulting fees from Astute Medical/BioMerieux, outside the submitted work. G.C. has received funding from the National Institutes of Health unrelated to the submitted work. L.S.C. was previously the chief medical officer of La Jolla Pharmaceuticals Inc. C.-C.H.C. has received grants from National Institutes of Health unrelated to this study. P.P. reports no conflicts of interest."